Access cutting-edge locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration treatment through this phase 1 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New York location
Preparing your pre-screening questions…
Access locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration treatment provided free
Check if you qualify for this locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration clinical trial in New York, NY
No-Cost Study Care
Local to New York
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Sponsor: Avistone Biotechnology Co., Ltd.
Yes, this clinical trial (NCT06716138) has an active research site in New York, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration treatment options in New York, NY, this clinical trial (NCT06716138) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration clinical trials near you to find additional studies recruiting in your area.
See all leukemia clinical trials recruiting in New York — not just this study.
Browse Leukemia Trials in New York →